Natco Pharma: Focusing On Complex Products

Hi Madhavojha,

Thanks for your post, Can you please help in understanding the numbers for 55 P/E and PAT assumption of around 300 Cr post revlimid.

25% of FY25 profit is 470 Cr (assumption of 25% EBIDTA/ profits are from Non-revlimid businesses) valuing company at 33-35 P/E post revlimid.

Disclosure: Invested and Biased.

4 Likes